Gland Pharma (GLAND) Share Price Fall Streak: Second Straight Session
- October 22, 2026
- Posted by: Kunal Singla
- Category: News
Gland Pharma Share Price Fall Streak is in its second straight session, with the latest traded price at Rs 2,854.30 and the cumulative move across the streak at -5.71%. Univest data confirms the move itself, though no company-specific trigger has been identified. The latest Gland Pharma Share Price Fall Streak also matters because the stock is trading lower while the broader valuation picture stays anchored to the same earnings and book-value base.
With a market capitalisation of Rs 49,952.91 crore, Gland Pharma Share Price Fall Streak is best read as a two-session pattern rather than a one-day move. For a reader, that distinction matters because consecutive lower sessions can change the way the market views the stock versus a single intraday decline. The latest Gland Pharma Share Price Fall Streak therefore deserves a close read across price action, fundamentals, sector context and peer positioning.
Gland Pharma (GLAND) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,854.3 |
| Previous Close | Rs 2,924.3 |
| Today's Move | -Rs 70.00 (-2.39%) |
| Open | Rs 2,900 |
| High | Rs 2,950.9 |
| Low | Rs 2,854.3 |
| Market Capitalisation | Rs 49,952.91 crore |
Gland Pharma Share Price Fall Streak opened at Rs 2,900.00, touched a high of Rs 2,950.90 and a low of Rs 2,854.30, before last trading at Rs 2,854.30. That placed the stock at the day’s low at the time of the latest update. Versus the previous close of Rs 2,924.30, the share price declined by Rs 70.00, or -2.39%. The latest move also keeps Gland Pharma Share Price Fall Streak below its streak-start base price of Rs 3,027.25, which puts the full two-session change at -5.71%.
The market capitalisation stands at Rs 49,952.91 crore, and the company sits in the Large Cap category. In the context of Gland Pharma Share Price Fall Streak, the session range shows that the stock spent the update at the lower end of the day rather than near the opening level. That makes today’s share price fall part of a broader two-session decline, not an isolated print. The next step is to see whether the valuation base or peer comparison gives any useful context for the streak.
What the Consecutive Declines Show
Gland Pharma Share Price Fall Streak now reflects a second straight session of lower pricing, and that is the key differentiator from a normal one-day decline. The cumulative move of -5.71% from Rs 3,027.25 to Rs 2,854.30 shows that the current price has moved materially away from the streak-start level. For readers tracking Gland Pharma Share Price Fall Streak, the main point is not just the daily change but the persistence of the move across two sessions.
According to latest Univest figures, the streak tells a simple market story: the same earnings base is now being priced at a lower share price than it was two sessions ago. That does not establish a reason for the move, but it does show that the decline is continuing across successive trading sessions. In a streak context, that is more informative than looking at one day on its own, and it makes the stock worth reading alongside fundamentals and sector multiples.
Gland Pharma (GLAND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 49,952.91 crore |
| P/E Ratio | 42.75x |
| P/B Ratio | 4.54x |
| ROE | 10.56% |
| ROCE | 14.96% |
| EPS | Rs 68.41 |
| Book Value Per Share | Rs 644.16 |
| Dividend Yield | 0.68% |
Gland Pharma (GLAND) fundamental metrics show P/E 42.75x, P/B 4.54x, ROE 10.56%, ROCE 14.96%. Read together, these ratios describe the company’s position rather than a recommendation.
Gland Pharma has a market capitalisation of Rs 49,952.91 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 42.75x, P/B at 4.54x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 10.56% and ROCE of 14.96%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 68.41, book value per share of Rs 644.16, dividend yield of 0.68%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.23x, median ROE of 11.33%, median ROCE of 13.25%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 42.75x |
| Benchmark Median P/E | 31.23x |
| Benchmark Average P/E | 45.39x |
| Benchmark P/E Range | 3.4x to 616.23x |
| Company P/B Ratio | 4.54x |
| Benchmark Median P/B | 2.71x |
| Benchmark Average P/B | 4.05x |
| Company ROE | 10.56% |
| Benchmark Median ROE | 11.33% |
| Benchmark Average ROE | 10.08% |
| Company ROCE | 14.96% |
| Benchmark Median ROCE | 13.25% |
| Benchmark Average ROCE | 12.99% |
| Company Market Capitalisation | Rs 49,952.91 crore |
| Benchmark Median Market Cap | Rs 771.43 crore |
| Benchmark Average Market Cap | Rs 13,461.56 crore |
Gland Pharma (GLAND) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Gland Pharma (GLAND) has a P/E ratio of 42.75x, which is above the benchmark median of 31.23x, a difference of +36.89%. The P/E comparison frames valuation; it is not a signal to buy or sell.
Gland Pharma (GLAND) has a ROE of 10.56%, which is below the benchmark median of 11.33%, a difference of -6.8%. Gland Pharma (GLAND) has a ROCE of 14.96%, which is above the benchmark median of 13.25%, a difference of +12.91%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,18,683.95 | 34.61 | 4.84 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,41,310.94 | 83.04 | 13.75 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,73,078.79 | 78.96 | 19.19 | 26.76 | 19.27 |
| Laurus Labs | LAURUSLABS | 1,11,433.99 | 99.43 | 19.28 | 18.31 | 18.2 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,022.18 | 24.7 | 4.13 | 19.69 | 21.39 |
Gland Pharma (GLAND) has a P/E ratio of 42.75x compared with the displayed peer median of 78.96x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 10.56% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 14.96% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Gland Pharma (GLAND) has a market capitalisation of Rs 49,952.91 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Gland Pharma
- Gland Pharma Share Price Fall Streak is now in a second straight session, which makes the pattern more important than a one-off decline.
- The latest traded price of Rs 2,854.30 is below the previous close of Rs 2,924.30 and below the streak-start base price of Rs 3,027.25.
- The company still carries a P/E of 42.75, a P/B of 4.54 and a market cap of Rs 49,952.91 crore, so the valuation lens remains relevant.
- ROCE of 14.96% remains above the same-industry median of 13.25%, which helps frame the fundamental backdrop.
- Peer comparison shows Gland Pharma Share Price Fall Streak sitting between lower- and higher-valued pharmaceutical names, so relative placement is still useful.
About Gland Pharma
Gland Pharma operates in Pharmaceuticals & Drugs within Healthcare, and that is the right business lens for reading Gland Pharma Share Price Fall Streak. The company’s listed identity is anchored in the pharmaceutical sector, where valuation often reflects product mix, execution quality and return metrics. For this article, the key point is not a broad corporate profile but how the business context supports the interpretation of the recent share price decline. The company’s market capitalisation, earnings base and book value help place the streak inside a large listed healthcare name rather than a small speculative move.
Track Gland Pharma Share Price on Univest
Use Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
You can track Gland Pharma Share Price on Univest for live updates, valuation ratios, 52-week levels and market insights in one place. Gland Pharma Share Price Fall Streak, as well as the company’s fundamental ratios and peer context, can be followed alongside broader market moves. Univest keeps the stock page updated so readers can review the latest traded price and the valuation backdrop without switching between multiple screens.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Gland Pharma Share Price falling today?
Ans. According to Univest data, Gland Pharma Share Price Fall Streak is in a second straight session of decline, but no company-specific catalyst is established. The latest traded price is Rs 2,854.30, below the previous close of Rs 2,924.30.
What is the latest traded price of Gland Pharma Share Price?
Ans. Gland Pharma Share Price Fall Streak last traded at Rs 2,854.30 as of 22 October 2026 at 1:23:05 PM IST. That is lower than the previous close of Rs 2,924.30 and keeps the streak in focus.
How much has Gland Pharma Share Price fallen across the streak?
Ans. Gland Pharma Share Price Fall Streak has declined by -5.71% across two consecutive sessions from a streak-start base price of Rs 3,027.25. The move is a cumulative pattern, not just a one-session change.
What is Gland Pharma market capitalisation?
Ans. Gland Pharma has a market capitalisation of Rs 49,952.91 crore. That places Gland Pharma Share Price Fall Streak within the Large Cap category and well above the same-industry median market cap of Rs 771.43 crore.
What does Gland Pharma P/E ratio show now?
Ans. Gland Pharma Share Price Fall Streak carries a P/E ratio of 42.75. That is above the same-industry median of 31.23 and slightly below the benchmark average of 45.39, so the valuation stays relatively elevated.
How does Gland Pharma P/B ratio compare with the sector?
Ans. The company’s P/B ratio is 4.54, above the same-industry median of 2.71 and above the benchmark average of 4.05. For Gland Pharma Share Price Fall Streak, that means the market is still valuing the stock above the sector midpoint.
What are the key profitability ratios for Gland Pharma ?
Ans. Gland Pharma reports ROE of 10.56% and ROCE of 14.96%. In the context of Gland Pharma Share Price Fall Streak, ROE is slightly below the benchmark median, while ROCE is above it.
How do Gland Pharma earnings per share and book value look?
Ans. EPS is Rs 68.41 and book value is Rs 644.16. Those per-share figures help frame Gland Pharma Share Price Fall Streak because the streak changes the price, while the earnings and book-value base stays the same.
Should investors track Gland Pharma Share Price on Univest?
Ans. Yes, because Gland Pharma Share Price Fall Streak now spans two sessions and sits alongside valuation, sector and peer context. Univest lets readers follow the latest traded price, market cap, ratios and benchmark placement in one view.
